Quest Diagnostics (DGX) Stock
Key stats
- Market cap
- $28.12B
- Price / Earnings ratio
- 24.9x
- EPS (TTM)
- $10.18
- Volume
- Loading
- 52-week high
- $256.99
- 52-week low
- $171.18
- Dividend yield
- 1.33%
- Dividend amount (latest)
- $0.86
- EPS vs analyst estimate
- +3.6%Q3 FY25 · $2.60 vs $2.51
Source: third-party data provider, as of November 7, 2026
EPS estimate: analyst consensus
Compare with DGX
Recent news

Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
DGX

PRIVACY ALERT: AWKO Law LLP Investigates Quest Diagnostics for Data Breach of Patient Records
PRIVACY ALERT: AWKO Law LLP Investigates Quest Diagnostics for Data Breach of Patient Records
DGX

Lab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach
Lab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach
DGX

Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
DGX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 66.14
- MACD 12/26/9
- 4.74
- EMA 9 of MACD
- 3.25
- MACD histogram
- 1.49
- SMA 50
- $239.15
- Price above SMA 50
- EMA 50
- $238.84
- Price above EMA 50
- SMA 200
- $213.42
- Price above SMA 200
- EMA 200
- $215.11
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $2.74 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
DGX

PRIVACY ALERT: AWKO Law LLP Investigates Quest Diagnostics for Data Breach of Patient Records
PRIVACY ALERT: AWKO Law LLP Investigates Quest Diagnostics for Data Breach of Patient Records
DGX

Lab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach
Lab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach
DGX

Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
DGX

DGX Q3 Earnings & Revenues Beat, '26 View Raised, Stock Down in Pre-Market
DGX Q3 Earnings & Revenues Beat, '26 View Raised, Stock Down in Pre-Market
DGX

What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call
What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call
DGX

Quest Diagnostics: 3 Key Takeaways for Long-Term Investors
Quest Diagnostics: 3 Key Takeaways for Long-Term Investors
DGX

Why Quest's 'Good Enough' Third Quarter Wasn't Actually Enough
Why Quest's 'Good Enough' Third Quarter Wasn't Actually Enough
DGX

Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates
Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates
DGX

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
DGX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. James E. Davis | Chairman, CEO & President | 1963 |
| Mr. Sam A. Samad | Executive VP & CFO | 1970 |
| Mr. Michael E. Prevoznik J.D. | Senior VP & General Counsel | 1962 |
| Ms. Catherine T. Doherty | Executive Vice President of Regional Businesses | 1963 |
| Mr. Karthik Kuppusamy Ph.D. | Senior Vice President of Clinical Solutions | 1970 |
| Mr. Michael J. Deppe | Senior VP, Corporate Controller & Chief Accounting Officer | 1967 |
| Mr. Murali Balakumar | Senior VP and Chief Information & Digital Officer | — |
| Ms. Damini Chokshi | Vice President of Investor Relations | — |
| Ms. Kristin Lee Wallace Esq. | Senior VP & Chief Compliance Officer | — |
| Mr. Garry Clark | Senior VP and Chief Marketing & Communications Officer | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 66.14
- MACD 12/26/9
- 4.74
- EMA 9 of MACD
- 3.25
- MACD histogram
- 1.49
- SMA 50
- $239.15
- Price above SMA 50
- EMA 50
- $238.84
- Price above EMA 50
- SMA 200
- $213.42
- Price above SMA 200
- EMA 200
- $215.11
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $245.00
- Average
- $255.00
- High
- $260.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +4.5 | +14.4 | ||||||||||
| 2022 | -17.8 | -2.9 | +3.7 | -1.8 | +6.5 | -4.1 | -0.1 | -8.3 | -2.7 | +14.5 | +6.3 | +2.5 |
| 2023 | -4.7 | -6.9 | +1.8 | -2.7 | -4.9 | +4.9 | -2.8 | -2.3 | -6.6 | +7.6 | +3.5 | +1.3 |
| 2024 | -8.8 | -1.8 | +6.8 | +2.5 | +3.2 | -3.0 | +3.8 | +6.3 | -1.1 | +0.6 | +4.7 | -6.6 |
| 2025 | +8.0 | +6.4 | -4.4 | +5.3 | -2.2 | +3.0 | -6.6 | +6.3 | +6.6 | -3.4 | +5.8 | -5.6 |
| 2026 | +7.6 | +14.5 | -6.8 | -1.8 | +1.2 | +10.3 | +7.9 | +3.6 | -1.3 | +9.0 | +1.6 |
Corporate actions
Upcoming
No upcoming corporate actions for DGX



